INVO stock is up alongside earnings results

 Invo Bioscience (NASDAQ:INVO) stock is rocketing higher on Wednesday alongside its earnings report for the fourth quarter of 2023.

The healthcare services fertility company reported a net loss of $2 million during the quarter. That’s an improvement over its net loss of $2.8 million from the same period of the year prior.

Invo Bioscience reported revenue of $1.38 million for Q4 2023, a massive 397% increase over its Q4 2022 revenue of $278,142.

Invo Bioscience CEO Steve Shum said the following in the earnings report:

“During 2023, our revenue increased to more than $3.0 million, a 267% increase from the previous year, and included approximately 4.5 months of revenue from our Wisconsin revenue. In total, revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was more than $4.3 million.”

https://investorplace.com/2024/04/why-is-invo-bioscience-invo-stock-up-85-today/